Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics, a clinical stage biotechnology company, has appointed Vaughn Himes as executive vice president of technical operations and promoted Morris Rosenberg to executive vice president of process sciences.
Subscribe to our email newsletter
As executive vice president of technical operations, Dr Himes will oversee Seattle Genetics’s manufacturing, supply chain and quality assurance and control functions. Previously, Dr Himes was with Zymogenetics, most recently as senior vice president of technical operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development.
Dr Rosenberg joined Seattle Genetics in July 2001 and has overseen significant growth of the company’s development organization, including the process development, quality assurance and control, analytical biochemistry, formulation and manufacturing functions. Previously, he was with Eli Lilly, Biogen (now Biogen Idec) and Invitron.
Clay Siegall, president and CEO of Seattle Genetics, said: “Vaughn brings a strong background in commercial manufacturing and supply chain management, and has been involved in several successful drug approval submissions. Morris continues to demonstrate substantial operational expertise and leadership as Seattle Genetics has advanced its broad product pipeline into late-stage clinical trials. Together, these seasoned executives will play a key role in guiding our development and manufacturing initiatives across our pipeline, including our SGN-35 new drug application.”